| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |